[SCHEDULE 13G/A] MediWound Ltd. SEC Filing

Rhea-AI Filing Summary

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon report beneficial ownership of 570,326 MediWound common shares, representing 5.2% of outstanding shares based on 10,793,057 shares. The position comprises 407,061 issued common shares and 163,265 shares issuable upon exercise of warrants. Each reporting person discloses shared voting and dispositive power over 407,061 shares and no sole voting or dispositive power. The reported warrants contain a blocker provision preventing exercise to the extent such exercise would raise beneficial ownership above 9.99%. The advisor and Mr. Salamon disclaim beneficial ownership of shares held by the fund.

Positive

• Material economic position disclosed: 570,326 shares representing 5.2% of class.
• Clear breakdown provided: 407,061 issued common shares and 163,265 shares issuable upon exercise of warrants.
• Voting/dispositive powers disclosed: Shared voting and dispositive power specified for reported shares.

Negative

• No sole control: Reporting persons state 0 sole voting power and 0 sole dispositive power.
• Warrant exercise constrained: Warrants include a 9.99% blocker that limits conversion and effective ownership.
• Disclaimers reduce direct control: The advisor and Mr. Salamon disclaim beneficial ownership of fund-held shares.

Insights

Financial Analyst

TL;DR: Reporting group holds a >5% economic stake in MediWound composed of common shares and exercisable warrants, but conversion is limited by a blocker.

The filing discloses a material economic position of 570,326 shares (5.2%) based on 10,793,057 outstanding shares. The stake breaks down into 407,061 issued common shares and 163,265 shares tied to warrants. Shared voting and dispositive power is reported over the issued shares while no sole voting or dispositive authority is claimed. The warrants include a contractual blocker that prevents exercises that would push beneficial ownership above 9.99%, which constrains potential dilution or control shifts.

Corporate Governance Expert

TL;DR: Despite a disclosed 5.2% position, shared powers and disclaimers limit unilateral governance influence by the reporting group.

The filing shows the reporting persons have shared voting and dispositive power over 407,061 common shares and explicitly report no sole voting or dispositive power. The advisor and portfolio manager disclaim beneficial ownership of the fund-held shares, indicating those shares are reported for disclosure rather than direct personal control. The presence of warrants increases potential economic exposure but the 9.99% blocker restricts conversion-driven governance changes.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

MediWound Ltd.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

M68830104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M68830104

1

Names of Reporting Persons

Rosalind Advisors, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 570,326.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 570,326.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

570,326.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: This percentage is calculated based upon 10,793,057 shares of the Issuers common stock outstanding as of December 31, 2024, in accordance with 20F filed on March 19, 2025. However, as more fully described in Item 4, the securities reported in rows 6, 8, and 9 show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8, and 9. (6) 407,061 shares of Common Stock 163,265 shares of Common Stock issuable upon exercise of warrants

SCHEDULE 13G

CUSIP No. M68830104

1

Names of Reporting Persons

SALAMON STEVEN A J

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 570,326.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 570,326.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

570,326.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (6) 407,061 shares of Common Stock 163,265 shares of Common Stock issuable upon exercise of warrants

SCHEDULE 13G

CUSIP No. M68830104

1

Names of Reporting Persons

Aharon Gil

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 570,326.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 570,326.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

570,326.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (6) 407,061 shares of Common Stock 163,265 shares of Common Stock issuable upon exercise of warrants

SCHEDULE 13G

CUSIP No. M68830104

1

Names of Reporting Persons

Rosalind Master Fund L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 570,326.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 570,326.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

570,326.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (6) 407,061 shares of Common Stock 163,265 shares of Common Stock issuable upon exercise of warrants

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MediWound Ltd.
(b)	Address of issuer's principal executive offices: 42 HAYARKON STREET, 42 HAYARKON STREET, YAVNE, ISRAEL, 8122745.
Item 2.
(a)	Name of person filing: Rosalind Advisors, Inc. Advisor to RMF Rosalind Master Fund L.P. RMF Steven Salamon President Steven Salamon is the portfolio manager of the Advisor which advises RMF. Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.
(b)	Address or principal business office or, if none, residence: Rosalind Advisors, Inc. 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada Rosalind Master Fund L.P. P.O. Box 309 Ugland House, Grand Cayman KY1-1104, Cayman Islands Steven Salamon 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada Gilad Aharon 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada
(c)	Citizenship: Steven Salamon Ontario, Canada Gilad Aharon Ontario, Canada
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: M68830104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information as of the date of the event which requires filing of this statement required by Items 4a to c is set forth in Rows 7 to 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 13 of the cover page for each Reporting Person is based upon 10,793,057 shares of the Issuers common stock outstanding as of December 31, 2024, in accordance with 20F filed on March 19, 2025. Rosalind Master Fund L.P. may have been deemed to have the beneficial ownership of 407,061 shares of common stock representing the beneficial ownership of approximately 3.8% of the common stocks as mentioned above, which excludes the 163,265 shares issuable upon the exercise of warrants because they contain a blocker provision under which the holder thereof does not have the right to exercise any of the warrant to the extent that such exercise would result in beneficial ownership by the holder in excess of 9.99% of the Common Stock. Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.
(b)	Percent of class: Rosalind Advisors, Inc. 5.2% Rosalind Master Fund L.P. 5.2% Steven Salamon 5.2% Gilad Aharon 5.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: Rosalind Advisors, Inc. 407,061 shares of Common Stock Rosalind Master Fund L.P. 407,061 shares of Common Stock Steven Salamon 407,061 shares of Common Stock Gilad Aharon 407,061 shares of Common Stock
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: Rosalind Advisors, Inc. 407,061 shares of Common Stock Rosalind Master Fund L.P. 407,061 shares of Common Stock Steven Salamon 407,061 shares of Common Stock Gilad Aharon 407,061 shares of Common Stock
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Rosalind Advisors, Inc.

Signature:	Steven Salamon
Name/Title:	President
Date:	08/12/2025

SALAMON STEVEN A J

Signature:	Steven Salamon
Name/Title:	Steven Salamon
Date:	08/12/2025

Aharon Gil

Signature:	Gil Aharon
Name/Title:	Gil Aharon
Date:	08/12/2025

Rosalind Master Fund L.P.

Signature:	Mike McDonald
Name/Title:	Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:	08/12/2025

FAQ

What stake does Rosalind hold in MediWound (MDWD)?

Rosalind and associated reporting persons beneficially own 570,326 shares (5.2%) of MediWound common stock based on 10,793,057 shares outstanding, consisting of 407,061 common shares and 163,265 shares issuable upon exercise of warrants.

Do the reporting persons have sole voting power over MDWD shares?

No. The filing reports 0 shares with sole voting power and shared voting power of 407,061 shares.

Are the warrants exercisable without restriction?

No. The reported warrants contain a blocker provision preventing exercise to the extent such exercise would result in beneficial ownership above 9.99%.

Who filed the Schedule 13G/A for MDWD?

Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon are the reporting persons listed in the filing.

Does the advisor claim direct ownership of the fund's shares?

No. The filing states that Rosalind Advisors, Inc. and Mr. Salamon disclaim beneficial ownership of the shares held by the fund.